Quarterly report [Sections 13 or 15(d)]

Acquisitions - HilleVax Acquisition - Allocation of the purchase consideration (Details)

v3.25.3
Acquisitions - HilleVax Acquisition - Allocation of the purchase consideration (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 17, 2025
Sep. 30, 2025
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Asset acquisition          
Cash and cash equivalents   $ 45,189 $ 45,189   $ 101,654
Trade and other receivables, net   3,573 3,573   1,839
Prepaid expenses and other current assets   967 967   2,076
Short-term restricted cash   45,288 45,288   1,330
Long-term restricted cash   40,076 40,076   3,432
Other assets - long term   879 879   1,861
Accrued and other liabilities   (4,134) (4,134)   (5,752)
Operating lease liabilities   (2,508) (2,508)   (446)
Long-term operating lease liabilities   (20,678) (20,678)   $ (483)
Gains on acquisitions   $ (18,004) $ (18,004) $ (19,316)  
HilleVax          
Asset acquisition          
Cash and cash equivalents $ 102,752        
Trade and other receivables, net 275        
Prepaid expenses and other current assets 64        
Short-term restricted cash 5,244        
Long-term restricted cash 38,063        
Other assets - long term 26        
Accrued and other liabilities (663)        
Operating lease liabilities (1,879)        
Long-term operating lease liabilities (20,646)        
Net assets acquired 123,236        
Gains on acquisitions (17,887)        
Total purchase consideration $ 105,349